Valganciclovir

Drugs

Volumn 61, Issue 8, 2001, Pages 1145-1150

  Curran, M ^a   Noble, S ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; GANCICLOVIR; VALGANCICLOVIR;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; AREA UNDER THE CURVE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TOLERABILITY; FEVER; HEADACHE; HUMAN; INSOMNIA; NAUSEA; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; RETINA DETACHMENT; RETINITIS; REVIEW; THROMBOCYTOPENIA; VOMITING;

EID: 0034933504     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161080-00013     Document Type: Review

References (14)

1. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: Recommendations of an international panel
2. Current and novel agents for the treatment of cytomegalovirus retinitis
3. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients
4. Ganciclovir: An update of its therapeutic use in cytomegalovirus infection
5. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2
6. Ganciclovir: An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients
7. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects
8. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers
9. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients
10. Valganciclovir (VGCV) vs IV ganciclovir (GCV) as induction therapy for newly diagnosed cytomegalovirus (CMV) retinitis: A randomised, controlled study
11. Comparative tolerability of therapies for cytomegalovirus retinitis
12. Current management of cytomegalovirus disease in patients with AIDS
13. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy (HAART)